Vtorichnyy osteoporoz pri revmaticheskikh zabolevaniyakh
- Authors: Men'shikova I.V1
-
Affiliations:
- Issue: No 10 (2014)
- Pages: 34-39
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286999
- ID: 286999
Cite item
Open Access
Access granted
Abstract
The problem of osteoporosis (OP) remains relevant for decades because of its high prevalence in the population and the growth of the number of osteoporotic fractures. Rheumatic diseases (RD) and glucocorticosteroids (GCS) used for their treatment remain one of the most common causes of secondary OP, which in turn complicates the course of RD. The mechanisms of the development of the secondary OP and the GCS-induced OP are analyzed. Russian and international recommendations for the prevention and treatment of this disease are presented. Special attention is paid to modern drugs for the treatment of OP.
Full Text
References
- Czerwinsky E., Badursky J.E., Marzinovska-Suchowierska E., Osiniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop. Traumatol. Rehabil. 2007; 9(4): 337-56.
- World Health Organization. Assessment of osteoporosis at the primary health care level. Summary report of a WHO Scientific Group. WHO, Geneva, 2007.
- Kanis J.A., Johanson H., Oden A., Johnel O., et al. A meta-analysis of prior corticosteroid use and fracture risk. Bone Miner Res. 2000; 19: 893-99.
- Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2001; 2: 65-73.
- Boyle W.J., Simonet W.S., Lacely D.L. Osteoclast differentiation and activation. Nature. 2003; 423: 337-42.
- Geusens P.P., Landew R.B., Garnero P., et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis patients predicts later joint destruction. Arthritis Rheum. 2006; 54: 1772-77.
- Geusens P., van Brussel M.S., Lems W.F. Osteoporosis and fracture risk: pathogenesis, epidemiology, clinical aspects and diagnosis. EULAR Compendium on Rheumatic Diseases. BMJ Publishing Group, 2009. P. 523-38.
- Brosch S., Redlich K., Pletschmann P. Pathogenesis of osteoporosis in rheumatoid arthritis. Acta Med. Austriaca. 2003; 30(1): 1-5.
- Cortet B., Flipo R.M., Duquesnoy D., Declambre B. Bone tissue in rheumatoid arthritis (1 and 2). Rev. Rheum. 1995; 62: 197-211.
- Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблема остеопороза в ревматологии. М., 1997. 429 с.
- Bultnik I.E., Lems W.F., Kostense P.J., et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005; 52: 2044-50.
- Canalis E., Bilezikian J.P., Angeli A., Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone. 2004 34: 593-98.
- Patsan D., Loddenkemper K., Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone. 2001; 29(6): 498-505.
- Van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006; 79: 129-37.
- Compston J., Bowring C., Cooper A., et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guidline Group (NOGG) update 2013. Maturitas Jun 26 2013; [Medline].
- Остеопороз. Диагностика, профилактика и лечение. Под ред. О.М. Лесняк, Л.И. Беневоленкской. 2-е изд., перераб. и доп. М., 2010. 272 с.(Серия «Клинические рекомендации»).
- De Vries F., Bracke M., Leufkens G., et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007; 56(1): 208-14.
- Saag K.G., Shane E., Boonen S., et al. Teriparatid or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 2007; 357(20): 2028-39.
- Watts N.B., Bilezikian J.P., Camacho P.M., Greenspan S.L., Harris S.F., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr. Pract. 2010; 16(Suppl 3): 1-37.
- Roux Ch., Adami S. Osteoporosis treatment. EULAR Compendium on Rheumatic Diseases. BMJ. Publishing Group, 2009. P. 539-45.
- Shwartz E.M., Ritchlin C.T. Clinical development of anti-RANKL therapy. Arthritis Res. Ther. 2007; 9(Suppl 1): s7.
Supplementary files
